Stock A191420 TEGOSCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TegoScience Inc.

Equities

A191420

KR7191420009

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
18,210 KRW -3.45% Intraday chart for TegoScience Inc. -0.22% +24.22%
2023 TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index CI
2023 TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 287,053 189,608 245,803 174,032 97,680 117,376
Enterprise Value (EV) 1 265,373 167,376 222,914 153,766 76,523 98,006
P/E ratio -157 x 221 x 132 x 1,274 x 370 x -50.5 x
Yield - - - - - -
Capitalization / Revenue 36.6 x 29.9 x 28 x 21 x 12.7 x 15.1 x
EV / Revenue 33.8 x 26.4 x 25.4 x 18.5 x 9.97 x 12.6 x
EV / EBITDA 220 x 179 x 101 x 313 x 94.4 x -154 x
EV / FCF -39.7 x -1,289 x 246 x 631 x 193 x -39.4 x
FCF Yield -2.52% -0.08% 0.41% 0.16% 0.52% -2.53%
Price to Book 6.15 x 3.97 x 4.99 x 3.58 x 2.01 x 2.53 x
Nbr of stocks (in thousands) 8,075 8,086 8,086 8,038 8,007 8,007
Reference price 2 35,550 23,450 30,400 21,650 12,200 14,660
Announcement Date 3/19/19 3/30/20 3/19/21 3/23/22 3/22/23 3/27/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,850 6,346 8,789 8,300 7,678 7,772
EBITDA 1 1,206 936.3 2,210 490.7 811 -637.6
EBIT 1 872.8 346 1,580 -98.01 229.6 -1,185
Operating Margin 11.12% 5.45% 17.98% -1.18% 2.99% -15.24%
Earnings before Tax (EBT) 1 -552.4 864.4 2,086 66.21 201.6 -2,563
Net income 1 -1,826 855.6 1,852 139.3 264.5 -2,323
Net margin -23.26% 13.48% 21.07% 1.68% 3.44% -29.88%
EPS 2 -226.3 105.9 229.9 17.00 33.00 -290.1
Free Cash Flow 1 -6,681 -129.8 905.1 243.7 396.9 -2,484
FCF margin -85.11% -2.05% 10.3% 2.94% 5.17% -31.96%
FCF Conversion (EBITDA) - - 40.96% 49.66% 48.94% -
FCF Conversion (Net income) - - 48.87% 174.98% 150.06% -
Dividend per Share - - - - - -
Announcement Date 3/19/19 3/30/20 3/19/21 3/23/22 3/22/23 3/27/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 21,680 22,232 22,889 20,267 21,157 19,370
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -6,681 -130 905 244 397 -2,484
ROE (net income / shareholders' equity) -4.51% 1.76% 3.77% 0.1% 0.53% -4.93%
ROA (Net income/ Total Assets) 1.15% 0.45% 2% -0.12% 0.28% -1.48%
Assets 1 -159,245 190,213 92,791 -115,278 94,334 157,267
Book Value Per Share 2 5,781 5,914 6,093 6,046 6,070 5,803
Cash Flow per Share 2 156.0 202.0 201.0 325.0 101.0 264.0
Capex 1 917 60.2 92.5 16.2 15.5 36.1
Capex / Sales 11.68% 0.95% 1.05% 0.2% 0.2% 0.46%
Announcement Date 3/19/19 3/30/20 3/19/21 3/23/22 3/22/23 3/27/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
TEGOSCIENCE INC. Stock TegoScience Inc.
+24.22% 105M
CSL LIMITED Stock CSL Limited
-2.29% 89.87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.57B
BIOGEN INC. Stock Biogen Inc.
-13.07% 32.75B
UCB Stock UCB
+63.05% 26.47B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.25B
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 9.11B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A191420 Stock
  4. Financials TegoScience Inc.